Activities of Bolesław G. PIECHA related to 2016/2057(INI)
Plenary speeches (2)
Options for improving access to medicines (debate) PL
Options for improving access to medicines (debate) PL
Amendments (13)
Amendment 93 #
Motion for a resolution
Recital E
Recital E
E. whereas the aim of intellectual property is to benefit society, guaranteeing investment returns to promote innovation, and whereas there isare concerns about the abuse/misuse thereof;
Amendment 169 #
Motion for a resolution
Paragraph 2
Paragraph 2
2. Regrequests that the research priorities of the pharmaceutical industry are profit- oriented rather than patient-orbe consistently oriented towards making European production competitive as well as sustainable and affordable for the patiented;
Amendment 262 #
Motion for a resolution
Paragraph 8 a (new)
Paragraph 8 a (new)
8a. Stresses that the development of generic and biosimilar medicines is often the only way to allow poorer parts of the population access pharmaceutical products;
Amendment 313 #
Motion for a resolution
Paragraph 13
Paragraph 13
13. Believes that a fair price should cover the cost of the drug development and production, plus a margin of profit, taking also into account the dedicated population, its efficiency and the level of innovation;
Amendment 345 #
Motion for a resolution
Paragraph 15
Paragraph 15
15. Recalls that transparency in all EU and national institutions and agencies is crucial, and that experts involved in the authorisation process, pricing and setting the reimbursement rates should have no conflicts of interest;
Amendment 473 #
Motion for a resolution
Paragraph 24
Paragraph 24
24. Calls on the Commission to set up a framework to promote, guarantee and reinforce the competitiveness and use of generic medicineand biosimilar medicines in sustainable market conditions, guaranteeing their faster entry onto the market and monitoring unfair practices in accordance with Articles 101 and 102 of the TFEU, and to present a biannual report in this regard;
Amendment 498 #
Motion for a resolution
Paragraph 25
Paragraph 25
25. Calls on the Commission to consider proposeing legislation on a European system forthese aspects of the health technology assessment as soon as possible, and towhich are relevant for the EU, in particular clinical evaluation, to better assess added-value medicines compared with the best available alternative; also calls on the Commission to harmonisework towards pricing and reimbursement criteria to takeaking into account the level of innovation and the social and economic cost-benefit analysis for all the Member States, and to put in place a European classification on the added value level of medicines;
Amendment 520 #
Motion for a resolution
Paragraph 27
Paragraph 27
27. Calls on the Council to increase cooperation between the Member States as regards price-setting procedures, in order to share information about prices, reimbursement, negotiation agreements and good practices and to avoid unnecessary administrative requirements and delays;
Amendment 549 #
Motion for a resolution
Paragraph 29
Paragraph 29
29. Calls on the Commission and the CouncilMember States to explore new measures to control prices, such as horizontal scanning and coordinfacilitating joint procurements;
Amendment 562 #
Motion for a resolution
Paragraph 31
Paragraph 31
31. Calls on the Commission to propose a new directive on transparency of price-setting procedures and reimbursement systems, taking into account the challenges of the market and the division of competences between the EU and its Member States;
Amendment 580 #
Motion for a resolution
Paragraph 34
Paragraph 34
34. Calls on the Commission to examine and compare, to the extent possible, the prices of medicines in the EU and to present an annual report to Parliament in this regard;
Amendment 584 #
Motion for a resolution
Paragraph 35
Paragraph 35
Amendment 602 #
Motion for a resolution
Paragraph 36
Paragraph 36
36. Calls on the Commission to analyse the causes of shortages, to establish a list of essential medicines and monitor compliance with Article 81 of Directive 2001/83/EU on shortages of supply, and to promote the supply of generic and biosimilar medicines;